D2 dopaminergic regulation of striatal preproenkephalin mRNA levels is mediated at least in part through cholinergic interneurons.
The effect of administration of the muscarinic antagonist scopolamine on the increase in striatal preproenkephalin (PPE) mRNA following a 6-hydroxydopamine (6-OHDA) lesion or chronic D2 dopamine (DA) antagonist treatment was examined by dot-blot hybridization. Administration of scopolamine dose-dependently attenuated the 6-OHDA lesion-induced increase in striatal PPE mRNA. Administration of the D2 DA antagonist eticlopride to naive rats increased striatal PPE mRNA in a dose- and time-dependent fashion. Chronic coadministration of scopolamine attenuated the eticlopride-induced increase in striatal PPE mRNA. Chronic administration of scopolamine alone did not alter striatal PPE mRNA levels. In contrast, chronic administration of eticlopride, scopolamine or the two combined decreased striatal preprotachykinin (PPT) mRNA to the same extent, suggesting that there was no direct interaction between D2 dopaminergic and cholinergic mechanisms in the regulation of striatal PPT mRNA. These data indicate that DA differentially regulates striatal PPE and PPT mRNA and suggest that dopaminergic regulation of striatal PPE mRNA is mediated in part through D2 DA effects on striatal cholinergic neurons.
Pollack
A E
AE
Department of Neuroscience, University of Virginia Health Sciences Center, Charlottesville 22908.
Wooten
G F
GF
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D015152:Blotting, Northern; D003342:Corpus Striatum / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004745:Enkephalins / Q000235:genetics*; D007395:Interneurons / Q000187:drug effects / Q000502:physiology*; D007700:Kinetics; D008297:Male; D008959:Models, Neurological; D009693:Nucleic Acid Hybridization; D015345:Oligonucleotide Probes; D016627:Oxidopamine / Q000494:pharmacology*; D010761:Phosphorus Radioisotopes; D011498:Protein Precursors / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D017448:Receptors, Dopamine D2; D012457:Salicylamides / Q000494:pharmacology*; D012601:Scopolamine / Q000494:pharmacology*
D004745:Enkephalins; D015345:Oligonucleotide Probes; D010761:Phosphorus Radioisotopes; D011498:Protein Precursors; D012333:RNA, Messenger; D011954:Receptors, Dopamine; D017448:Receptors, Dopamine D2; D012457:Salicylamides; D016627:Oxidopamine; C033660:preproenkephalin; D012601:Scopolamine; C045989:eticlopride; D000109:Acetylcholine